Hospital data reveals a sharp rise in consultations related to hormonal health, erectile dysfunction and male fertility, highlighting growing awareness among younger men.
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Premium CBD+THC-infused gummies target stress relief, relaxation, and sleep recovery
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
